Scott Ely, MD, MPH
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Multiple myeloma
- Lymphoma
- Leukemia
My Specialties
- Hematopathology
Get to Know Me
I’m a board-certified and internationally recognized leader in hematopathology. This is a type of pathology which is responsible for diagnosing specific types of blood cancers, such as multiple myeloma, lymphoma, and leukemia.
A big part of my career has been dedicated to developing cancer drugs. My previous work has led to the development of palbociclib, a targeted drug for certain types of breast cancer. My work has also led to therapies for myeloma, such as CAR-T cell therapies, bispecifics, and Cereblon E3 ligase modulatory drugs (CELMoDs), which are a new class of drugs developed for treating multiple myeloma.
My current research is focused on developing precision medicine lab tests that help with treatment decisions for blood cancers, mainly myeloma.
I'm a pathologist, which is a doctor who uses a microscope to make a diagnosis from cell and tissue samples. I analyze these samples to learn the cause and effects of a health issue.
- Attending Physician
Conditions I Treat
- Multiple myeloma
- Lymphoma
- Leukemia
My Specialties
- Hematopathology
Education
- MD, Tulane University School of Medicine
- MPH, Tulane University School of Public Health and Tropical Medicine
Residencies
- Anatomic Pathology, Lenox Hill Hospital
- Clinical Pathology, Lenox Hill Hospital
Fellowships
- Hematopathology, Weill Cornell Medical Center, NewYork-Presbyterian Hospital
Board Certifications
- Anatomic Pathology
- Clinical Pathology
- Hematology
Awards and Honors
- Finalist, Cornell Venture Challenge, BR Venture Fund, SC Johnson College of Business, Cornell University (2013)
- M. Desmond Burke MD Award, Department of Pathology, Weill Cornell (2012)
- AMA/Burroughs-Welcome Award, AMA American Medical Association (1993)
- Ciba-Geigy Award, Sandoz/Novartis (1989)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, HMO
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO
This is a dual payer plan, which means 2 health insurance companies share this plan. MSK providers are out-of-network with UnitedHealthcare.
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO, HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO (City Employee Health Plans Gold and Gold Care Only)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, EPO
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
Learn more about the insurance plans that participate with MSK.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
Health plans can change at any time. Call the number on the back of your insurance card to see what your plan covers. Make sure it covers the MSK location where you’ll get care.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
- Flore O, Rafii S, Ely S, O’Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi’s sarcoma-associated herpesvirus. Nature. 1998;394(6693):588-592. PMID: 9707121.
- Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S. Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma. Cancer Res. 2005;65(24):11345-11353. *The first 2 authors contributed equally to this study and manuscript. PMID: 16357141.
- Niesvizky R, Badros AZ, BA, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Raptis A, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, DiLiberto M, Huang X, Jiang Y, Kim ST, Randolph S, and Chen-Kiang S. Phase 1/2 Study of CDK 4/6 Inhibitor Palbociclib (PD-0332991) With Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Leukemia & Lymphoma. 2015;56(12):3320-3328. PMID: 25813205.
- Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin; Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky, Tomer M. Mark. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Naïve Patients. Clinical Lymphoma, Myeloma and Leukemia. 2017;17(12) 825-833. PMID: 29051077.
- Forsberg, P. A., Hammes, A., Abbott, D., Sherbenou, D. W., Rossi, A., Jayabalan, D., … Ely, S. (2019). Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leukemia & Lymphoma, 60(8), 2085–2087. PMID: 30632821.
Visit PubMed for a full listing of Dr. Ely’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Scott Ely discloses the following relationships and financial interests:
-
Daiichi Sankyo
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].